Malmö-based digital healthcare provider Yazen, focusing on obesity treatment, has announced the acquisition of Danish healthcare company Medstart. The move marks Yazen’s entry into the Danish market and strengthens its presence in Norway, furthering its goal to become a leading player in obesity care across Europe.
Shared Approach to Obesity Care
Medstart, established in Denmark and Norway, has developed a model combining modern weight-loss medications with lifestyle interventions and support from multidisciplinary teams. This closely aligns with Yazen’s holistic approach, making the acquisition a strategic fit.
“Yazen’s systematic approach and impressive growth trajectory demonstrate what is needed to make a real difference in obesity care. I am excited to join forces with their international team and strengthen our position in Denmark,”
said Oliver Willacy, CEO and founder of Medstart.
Expansion Backed by Recent Investment
The acquisition follows Yazen’s recent € 19.5 million investment round, enabling the company to expand its offerings and reach new markets. Initially, Medstart will operate under its own brand, with plans for gradual integration into Yazen by 2025. Yazen also intends to launch its digital platform in Denmark, combining the strengths of both companies to enhance their care model.
“We are thrilled to work with Medstart’s skilled team and continue our shared mission of improving the lives of people with obesity. Together, we aim to provide patients in Denmark and Norway with the best possible care,”
said Fredrik Meurling, founder and CEO of Yazen
A Growing Need for Comprehensive Solutions
Obesity remains a significant global challenge, with millions affected and substantial societal costs. Yazen’s model integrates digital healthcare, specialist teams, and innovative GLP-1 and GLP-1/GIP medications, offering patients effective weight-loss solutions and long-term health improvements.
Since its founding in Sweden in 2021, Yazen reports it has treated over 20,000 patients, who have collectively lost more than 200 tons. The acquisition of Medstart represents a step forward in Yazen’s mission to expand access to its proven care model across Europe.
